Kiniksa Pharmaceuticals International (KNSA) Gross Margin (2021 - 2026)

Kiniksa Pharmaceuticals International's Gross Margin history runs 6 years deep, the most recent figure standing at 90.29% for Q1 2026.

• Quarterly Gross Margin rose 326.0% year-over-year to 90.29% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 89.31% (up 348.0% YoY) and the FY2025 annual result came in at 88.54%, up 293.0% from the prior year.
• Gross Margin was 90.29% for Q1 2026 at Kiniksa Pharmaceuticals International, up from 89.64% in the prior quarter.
• Across five years, Gross Margin topped out at 104.52% in Q4 2022 and bottomed at 81.35% in Q2 2022.
• A 5-year average of 89.16% and a median of 88.51% in 2023 frame the typical range for Gross Margin.
• Annual changes were most pronounced in 2022 — Gross Margin surged 2515 bps — and 2023, when it slumped 1602 bps.
• Kiniksa Pharmaceuticals International's Gross Margin stood at 104.52% in 2022, then dropped by 15 bps to 88.51% in 2023, then retreated by 4 bps to 85.4% in 2024, then gained by 5 bps to 89.64% in 2025, then climbed by 1 bps to 90.29% in 2026.
• Business Quant data shows KNSA's Gross Margin at 90.29% in Q1 2026, 89.64% in Q4 2025, and 88.8% in Q3 2025.